



October 1, 2009

PRESS RELEASE

FOR IMMEDIATE RELEASE

**Pharmacy Chain 36.6 and CV Protek signed the agreement on debts repayment
for the sum of 153.8 million roubles.**

Pharmacy Chain 36.6 and CV Protek have signed the agreement on conditions of repayment of the remained sum of debts which makes 153.8 million roubles.

On conditions of the signed agreement the debts will be extinguished till the end of 2009, this agreement became the completion phase in the series of negotiations on settlement of financial mutual relations on Pharmacy Chain 36.6 creditor debts before ZAO Protek.

For further information please refer to:

Irina Lavrova
Director,
Corporate Communications and Public Relations
Management company "Pharmacy Chain 36.6"

lavrova.i.n@366.ru
Phone (+7495) 797 86 86 ext. 1210
(+7495) 792 52 07

Or see the website:

www.pharmacychain366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of September 22, 2009 totaled USD 99,8 mln (according to RTS). Pharmacy Chain 36.6 operates more than 1000 stores in 29 regions and 90 cities in Russia.

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five pharmaceutical manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as of September 22, 2009 was USD 290 mln (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 is a participating member of the international retailers' organizations - NRF and NACDS.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.